Table 1. Relationships of miR-630 and Bcl-2 expression levels with clinico-pathological parameters, and the association between miR-630 and Bcl-2 expression levels in lung cancer patients.

			miR-630			Bcl-2
	No.		Low	High	P	Low	High	P
Age
< 65	57		28(49.1)	29(50.9)	0.851	24 (42.1)	33 (57.9)	0.572
≥ 65	57		29(50.9)	28(49.1)		27 (47.4)	30 (52.6)
Gender
Female	38		20(52.6)	18(47.4)	0.691	14 (36.8)	24 (63.2)	0.231
Male	76		37(48.7)	39(51.3)		37 (48.7)	39 (51.3)
Smoking status
Nonsmokers		55	29(52.7)	26(47.3)	0.574	22 (40.0)	33 (60.0)	0.326
Smokers		59	28(47.5)	31(52.5)		29 (49.2)	30 (50.8)
Tumor type
Adenocarcinoma		56	25(44.6)	31(55.4)	0.261	22 (39.3)	34 (60.7)	0.250
Squamous		58	32(55.2)	26(44.8)		29 (50.0)	29 (50.0)
Stage of Cancer
1		43	16(37.2)	27(62.8)	0.034	21 (48.8)	22 (51.2)	0.493
2–3		71	41(57.7)	30(42.3)		30 (42.3)	41 (57.7)
miR-630
Low		57				18 (31.6)	39 (68.4)	0.005
High		57				33 (57.9)	24 (42.1)